Senior Scientist, Histology and Bioanalytics

Company Summary:

FL87, Inc. is a privately held, early-stage biotechnology company developing a novel approach to gene therapy that can address currently untreatable diseases.

FL87 was founded by Flagship Pioneering, an innovation enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA), Syros Pharmaceuticals (SYRS), Seres Therapeutics (NASDAQ:MCRB), Generate Biomedicines, Tessera Tx, Evelo Biosciences (EVLO), and Indigo Agriculture.

Position Summary:

We are searching for an experienced Senior Scientist to lead bioanalytics for platform development and therapeutic proof-of-principle. More broadly, we are looking for an individual who enjoys working with animal models and brings scientific rigor, intellectual curiosity, enthusiasm, and a desire to innovate new nucleic acid therapeutics. This individual will have the opportunity to work in a dynamic and fast-paced entrepreneurial environment, working both independently and as part of a highly collaborative and rapidly growing team.

Key Responsibilities:

• Drive the execution and analysis of bioanalytics to assess efficacy, safety and biodistribution of novel nucleic acid therapeutics.
• Develop and validate key assays/analytics, including flow cytometry, qPCR, MSD, ELISA, other relevant analytics.
• Develop and execute histology multiplexed IHC/IF and RNAscope mixed modality methods including slide imaging and image analysis.
• Determine nucleic acid pharmacology at the tissue level, including developing preclinical datasets to drive mechanistic understanding of delivery and function.
• Provide scientific and technical perspectives to advance platform development.
• Effectively communicate experimental findings in oral, written, and visual formats.
• Work independently and collaboratively in a multidisciplinary team environment.

Qualifications:

• PhD in relevant discipline or BS in relevant disciple with 7+ years of industry experience. Level will be based on experience
• Deep experience developing and executing flow cytometry analysis of rodent tissue derives samples, including immune cells.
• Experience with histological tissue analysis (IHC/IF, ISH, H&E, etc.) including tissue harvest, embedding, sectioning, staining, imaging and image analysis
• Experience working in-house and with external partners/CROs to execute studies and develop new capabilities.
• Experience with tissue processing and ex vivo analytical assays such as ELISA, FACS, MSD, qPCR, etc.
• Experience with in vivo studies, ideally involving non-viral delivery and/or nucleic acid based therapeutics in rat, mouse, and NHP is a plus.
• Experience with various mouse and rat models of diseases is a plus.
• Experience performing in vivo procedures in rodents, including preparation and administration of therapeutics and collecting material (blood, tissue, etc.) for ex vivo analysis is a plus.
• Strong communication and interpersonal skills.
• Strong organizational, analytical, and problem-solving skills.
• Ability to thrive in a fast-paced, multidisciplinary, and rapidly growing biotech environment.

More About Flagship Pioneering

We are creative optimists and we would love for you to consider joining our team!  See all our open opportunities across Flagship Pioneering’s Ecosystem!

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture.  Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies. Le